Cancer Genetics, Inc. Announces Closing of Public Offering of 1,500,000 Shares of Common Stock

Published: Aug 20, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

RUTHERFORD, N.J., Aug. 19, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a diagnostics company focused on developing genomic-based, oncology tests and services, today announced the closing of its previously announced public offering of 1,500,000 shares of its common stock at a price to the public of $10.00 per share. The gross proceeds to Cancer Genetics from the offering were $15,000,000, before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics. Cancer Genetics has also granted the representative of the underwriters a 45-day option to purchase up to 225,000 additional shares of common stock from Cancer Genetics to cover over-allotments, if any.

Help employers find you! Check out all the jobs and post your resume.

Back to news